Novel Therapeutic Approaches for Myelodysplastic Syndromes: Going Beyond Hypomethylating Agents

Rami S. Komrokji, MD, reviews emerging clinical data and provides expert guidance on managing patients with myelodysplastic syndromes.
Rami S. Komrokji, MD
Released: June 3, 2019 Expiration: No longer available for credit

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Evaluate emerging treatment options for the management of patients with low-risk, intermediate-risk, or high-risk myelodysplastic syndromes
  • Describe novel therapeutic options for patients with myelodysplastic syndromes after failure of hypomethylating agents

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Celgene Corporation

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Rami S. Komrokji, MD

Senior Member, Vice Chair
Malignant Hematology
Section Head
Leukemia and MDS
H. Lee Moffitt Cancer Center & Research Institute
Professor
Department of Oncologic Sciences
University of South Florida
Tampa, Florida

Rami S. Komrokji, MD, has disclosed that he has received consulting fees from Celgene, Daiichi Sankyo, Jazz, Novartis, and Pfizer.

Staff

Terrence Fagan

Associate Scientific Director

Terrence Fagan, PhD, has no relevant conflicts of interest to report.
Joy Curzio

Editorial Contributor

Joy Curzio has disclosed that her spouse has ownership interest in Advaxis, Editas, and Oncosec.
Bing-e Xu, PhD

Scientific Director

Bing-E Xu, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with myelodysplastic syndromes.

Goal

The goal of this activity is to improve participants’ knowledge of and competence in integrating novel therapeutic approaches into the care of patients with myelodysplastic syndromes.

Accreditation

Joint Accreditation Statement

 

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 03, 2019, through June 02, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Download this short summary slideset of key topics in the evolving use of BCMA-targeted agents for RR multiple myeloma from Clinical Care Options.

Natalie S. Callander, MD Released: October 23, 2020

Clinical commentary by Dr. William Wierda on personalizing frontline treatment for chronic lymphocytic leukemia (CLL) from Clinical Care Options (CCO)

William G. Wierda, MD, PhD Released: October 22, 2020

Downloadable resource from CCO on the diagnosis and management of mycosis fungoides

Prof Julia Scarisbrick Released: October 21, 2020

Download this slideset to review the latest clinical data informing optimal management strategies for follicular lymphoma

Emily Bucholtz Headshot Emily Bucholtz, RPh Nichole Fisher Headshot Nichole Fisher, RN, BSN Jeff P. Sharman, MD Released: October 14, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue